This brand name is authorized in Israel
The drug BLASTOVIN contains one active pharmaceutical ingredient (API):
|
1
Vinblastine
UNII N00W22YO2B - VINBLASTINE SULFATE
|
|
Vinblastine appears to bind to or crystallise critical microtubular proteins of the mitotic spindle, thus preventing their proper polymerisation and causing metaphase arrest. In high concentrations, vinblastine also exerts complex effects on nucleic acid and protein synthesis. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01CA01 | Vinblastine | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CA Vinca alkaloids and analogues |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 1478 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
